Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine; Puccini, Alberto; Berger, Martin Dave; Tokunaga, Ryuma; Battaglin, Francesca; Soni, Shivani; McSkane, Michelle; Zhang, Wu; Lenz, Heinz-Josef (2018). Outlooks on Epstein-Barr virus associated gastric cancer. Cancer treatment reviews, 66, pp. 15-22. Elsevier 10.1016/j.ctrv.2018.03.006
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1-s2.0-S0305737218300331-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (746kB) |
Epstein-Barr virus associated gastric cancer (EBVaGC) comprises approximately 10% of gastric carcinomas. Multiple factors contribute to tumorigenesis, including EBV driven hypermethylation of tumor suppressor genes, inflammatory changes in gastric mucosa, host immune evasion by EBV and changes in cell cycle pathways. The unique molecular characteristics of EBVaGC, such as programmed death ligand 1 (PD-L1) overexpression, highlight the potential for using EBV as a biomarker for response to immunotherapy. Few studies have reported benefit from immunotherapy in EBV positive cancers, and clinical trials investigating the impact of checkpoint inhibitors in EBVaGC are currently underway. This review provides the most recent updates on molecular pathophysiology, epidemiology, clinical features and treatment advances pertaining to EBVaGC.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Berger, Martin Dave |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1532-1967 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Rebeka Gerber |
Date Deposited: |
28 Feb 2019 14:27 |
Last Modified: |
05 Dec 2022 15:24 |
Publisher DOI: |
10.1016/j.ctrv.2018.03.006 |
PubMed ID: |
29631196 |
Uncontrolled Keywords: |
Biomarker EBV Gastric cancer Immunotherapy PD-L1 Viruses |
BORIS DOI: |
10.7892/boris.124095 |
URI: |
https://boris.unibe.ch/id/eprint/124095 |
Actions (login required)
 |
Edit item |